Duchenne Muscular Dystrophy Treatment Market

The total diagnosed Duchenne Muscular Dystrophy prevalent population in the seven major makrets was found to be 27,685 in 2017.

As per DelveInsight, Duchenne Muscular Dystrophy Market is anticipated to grow promisingly well from USD 266.06 Million as estimated in 2017 for the study period of 2017-30.

The key pharmaceutical companies in the Duchenne Muscular Dystrophy Market includes Sarepta, Nippon Shinyaku, Italfarmaco, FibroGen, Daichi Sankyo, Taiho Pharma, Catabasis Pharmaceuticals, Pfizer, Santhera Pharmaceuticals, Taiho Pharmaceuticals and others.

For more detailed information on Duchenne Muscular Dystrophy Treatment Market, visit:
https://www.delveinsight.com/blog/sarepta-therapeutics-dmd-market/